How Precisely Can Prostate Cancer Be Managed? / 대한배뇨장애요실금학회지
International Neurourology Journal
;
: S120-S130, 2016.
Article
Dans Anglais
| WPRIM
| ID: wpr-134030
ABSTRACT
Progress has been made in applying genetic information to disease management in the postgenomic era, and precision medicine is emerging in prostate cancer management. The prostate health index, the 4-kallikrein (4K) score, and the PCA3, TMPRSS2-ERG, and Prostarix tests have potential for refining prostate cancer screening in conjunction with traditional prostate-specific antigen testing. The Confirm MDx and PCA3 tests have shown promise in identifying men who need be rebiopsied after a primary negative biopsy. Oncotype DX, Prolaris, the biopsy-based Decipher prostate cancer test, and ProMark may improve predictive risk stratification in addition to the traditional Gleason score and tumor stage. Decipher and Prolaris may predict biochemical recurrence and metastasis after radical prostatectomy and possibly help identify patients who need adjuvant therapy. Androgen receptor splice variant 7 appears effective in guiding the selection of second hormonal manipulation with abiraterone or enzalutamide versus chemotherapy when treating metastatic castration-resistant prostate cancer.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Prostate
/
Prostatectomie
/
Tumeurs de la prostate
/
Récidive
/
Biopsie
/
Marqueurs biologiques
/
Récepteurs aux androgènes
/
Dépistage de masse
/
Antigène spécifique de la prostate
/
Prise en charge de la maladie
Type d'étude:
Étude pronostique
/
Étude de dépistage
Limites du sujet:
Humains
/
Mâle
langue:
Anglais
Texte intégral:
International Neurourology Journal
Année:
2016
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS